Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC).

被引：31
|
作者：
Janne, Pasi A.
Baik, Christina S.
Su, Wu-Chou
Johnson, Melissa Lynne
Hayashi, Hidetoshi
Nishio, Makoto
Kim, Dong-Wan
Koczywas, Marianna
Gold, Kathryn A.
Steuer, Conor Ernst
Murakami, Haruyasu
Yang, James Chih-Hsin
Kim, Sang-We
Vigliotti, Michele
Qi, Zhenhao
Qiu, Yang
Zhao, Lihui
Sternberg, David W.
Yu, Channing
Yu, Helena Alexandra
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Seattle Canc Care Alliance, Seattle, WA USA
[3] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[4] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[5] Kindai Univ Hosp, Osaka, Japan
[6] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan
[7] Seoul Natl Univ Hosp, Seoul, South Korea
[8] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA
[9] Univ Calif San Diego, San Diego, CA 92103 USA
[10] Emory Univ Hosp, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[11] Shizuoka Canc Ctr, Shizuoka, Japan
[12] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan
[13] Univ Ulsan, Coll Med, Seoul, South Korea
[14] Daiichi Sankyo Inc, Basking Ridge, NJ USA
[15] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9007
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9007
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pharmacokinetics, efficacy, and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)
    Yu, H. A.
    Cantero, F.
    Kim, B.
    Lee, M.
    Wu, E.
    Sternberg, D. W.
    Janne, P. A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1092 - S1093
  • [2] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer
    Janne, Pasi A.
    Baik, Christina
    Su, Wu-Chou
    Johnson, Melissa L.
    Hayashi, Hidetoshi
    Nishio, Makoto
    Kim, Dong-Wan
    Koczywas, Marianna
    Gold, Kathryn A.
    Steuer, Conor E.
    Murakami, Haruyasu
    Yang, James Chih-Hsin
    Kim, Sang-We
    Vigliotti, Michele
    Shi, Rong
    Qi, Zhenhao
    Qiu, Yang
    Zhao, Lihui
    Sternberg, David
    Yu, Channing
    Yu, Helena A.
    CANCER DISCOVERY, 2022, 12 (01) : 74 - 89
  • [3] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor-Resistant, EGFR-Mutated Non-Small Cell Lung Cancer (vol 12, pg 74, 2022)
    Janne, P. A.
    Baik, C.
    Su, W. C.
    Johnson, M., I
    Hayashi, H.
    Nishio, M.
    CANCER DISCOVERY, 2022, 12 (06) : 1598 - 1598
  • [4] Efficacy and safety of patritumab deruxtecan (HER3-DXd) in advanced/metastatic non-small cell lung cancer (NSCLC) without EGFR-activating mutations.
    Steuer, Conor Ernst
    Hayashi, Hidetoshi
    Su, Wu-Chou
    Nishio, Makoto
    Johnson, Melissa Lynne
    Kim, Dong-Wan
    Koczywas, Marianna
    Felip, Enriqueta
    Gold, Kathryn A.
    Murakami, Haruyasu
    Baik, Christina S.
    Kim, Sang-We
    Smit, Egbert F.
    Gigantone, Mark
    Kim, Ben
    Fan, Pang-Dian
    Qi, Zhenhao
    Wu, Elaine Y.
    Sternberg, David W.
    Janne, Pasi A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [5] Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) without EGFR-Activating Mutations
    Johnson, M. L.
    Steuer, C. E.
    Hayashi, H.
    Su, W. -C.
    Nishio, M.
    Kim, D. -W.
    Koczywas, M.
    Felip, E.
    Gold, K. A.
    Murakami, H.
    Baik, C. S.
    Kim, S. -W.
    Smit, E. F.
    Gigantone, M.
    Kim, B.
    Fan, P. -D.
    Qi, Z.
    Wu, E. Y.
    Sternberg, D.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E30 - E31
  • [6] Efficacy and Safety of the Novel HER3 Directed Antibody Drug Conjugate Patritumab Deruxtecan (HER3-DXd; U3-1402) in EGFR-mutated NSCLC
    Yu, H.
    Baik, C.
    Gold, K.
    Hayashi, H.
    Johnson, M.
    Koczywas, M.
    Murakami, H.
    Nishio, M.
    Steuer, C.
    Su, W.
    Yang, J. C.
    Karam, S.
    Qi, Z.
    Qiu, Y.
    Chen, S.
    Yu, C.
    Janne, P.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S107 - S107
  • [7] HERTHENA-Lung01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic EGFR-mutated NSCLC
    Yu, Helena A.
    Yang, James Chih-Hsin
    Hayashi, Hidetoshi
    Goto, Yasushi
    Felip, Enriqueta
    Reck, Martin
    Vigliotti, Michele
    Dong, Qian
    Cantero, Frederique
    Fan, Pang-Dian
    Kanai, Masayuki
    Sternberg, David W.
    Jaenne, Pasi A.
    FUTURE ONCOLOGY, 2023, 19 (19) : 1319 - 1329
  • [8] Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFRTKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
    Yu, H. A.
    Goto, Y.
    Hayashi, H.
    Felip, E.
    Yang, J. C. -H.
    Reck, M.
    Yoh, K.
    Lee, S. -H.
    Paz-Ares, L.
    Besse, B.
    Bironzo, P.
    Kim, D. -W.
    Johnson, M. L.
    Wu, Y. -L.
    Vigliotti, M.
    Dong, Q.
    Fan, P. -D.
    Shrestha, P.
    Sternberg, D. W.
    Sellami, D.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S53 - S54
  • [9] Dynamics of Molecular Markers in EGFR-Mutated NSCLC Patients Treated with Patritumab Deruxtecan (HER3-DXd; U3-1402)
    Janne, P.
    Baik, C.
    Hayashi, H.
    Su, W.
    Qi, Z.
    Enomoto, K.
    Karnoub, M.
    Yu, C.
    Qiu, Y.
    Yu, H. A.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S237 - S237
  • [10] Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC
    Yu, H. A.
    Baik, C.
    Kim, D. -W.
    Johnson, M. L.
    Hayashi, H.
    Nishio, M.
    Yang, J. C. -H.
    Su, W. -C.
    Gold, K. A.
    Koczywas, M.
    Smit, E. F.
    Steuer, C. E.
    Felip, E.
    Murakami, H.
    Kim, S. -W.
    Su, X.
    Sato, S.
    Fan, P. -D.
    Fujimura, M.
    Tanaka, Y.
    Patel, P.
    Sternberg, D. W.
    Sellami, D.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2024, 35 (05) : 437 - 447
12345